Monkeypox: A risk factor for inflammatory diseases?

Eur J Intern Med

Azienda Ospedaliera San Camillo Forlanini, Circonvallazione Gianicolense, Rome 00152, Italy. Electronic address:

Published: September 2024

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejim.2024.04.022DOI Listing

Publication Analysis

Top Keywords

monkeypox risk
4
risk factor
4
factor inflammatory
4
inflammatory diseases?
4
monkeypox
1
factor
1
inflammatory
1
diseases?
1

Similar Publications

Skin diseases impact millions of people around the world and pose a severe risk to public health. These diseases have a wide range of effects on the skin's structure, functionality, and appearance. Identifying and predicting skin diseases are laborious processes that require a complete physical examination, a review of the patient's medical history, and proper laboratory diagnostic testing.

View Article and Find Full Text PDF

Mpox, formerly known as monkeypox, is a zoonotic disease caused by the Mpox virus (MPXV), which has recently attracted global attention due to its potential for widespread outbreaks. Initially identified in 1958, MPXV primarily spreads to humans through contact with infected wild animals, particularly rodents. Historically confined to Africa, the virus has expanded beyond endemic regions, with notable outbreaks in Europe and North America in 2022, especially among men who have sex with men (MSM).

View Article and Find Full Text PDF

The monkeypox outbreak has grown beyond the regions in which it was considered endemic. It has spread from central and west Africa to non-endemic regions like Europe, America, and other parts of the world. It has recently been classified as a public health emergency of international concern.

View Article and Find Full Text PDF

Monkeypox (Mpox) is an infectious disease caused by the Mpox virus belonging to the Orthopoxvirus genus in the Poxviridae family and has been declared by the WHO as a global health emergency owing to its rapid spread during 2022 and 2023. All patients diagnosed with Mpox who were confirmed by PCR between July 2022 and April 2023 were included in this study. In total, 405 patients in whom clade 2 was identified were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!